Clik here to view.
BioDelivery on track for mid-year NDA filing
BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product...
View ArticleClik here to view.
MLV starts Sucampo Pharma at buy
MLV & Co. has initiated coverage of Sucampo Pharmaceuticals (NASDAQ:SCMP) with a “buy” rating and $14 price target, saying “this is no longer the old Sucampo that in years past had one drug with...
View ArticleClik here to view.
Elite eyes home run in abuse-resistant technology
After reinventing itself in 2011, Elite Pharmaceuticals (OTCBB:ELTP) has bounced back with a line of generic drugs and is banking on the development of abuse-resistant opioids and once-daily opioid...
View ArticleClik here to view.
Janney, Stifel start CARA Therapeutics at buy
Janney Capital Partners and Stifel Nicolas have initiated coverage CARA Therapeutics (NASDAQ:CARA) with “buy” ratings and a $25 fair value estimate and 12-month target price of $21, respectively. The...
View ArticleClik here to view.
DARA’s KRN5500 gets orphan drug designation
The FDA granted orphan drug designation to DARA BioSciences’ (NASDAQ:DARA) KRN5500 for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to...
View ArticleClik here to view.
Roth starts AcelRx Pharma at buy
Roth Capital Partners has initiated coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and $22 price target. The stock closed at $10.32 on Friday. “We believe Zalviso is a disruptive...
View ArticleClik here to view.
Titan implanting treatments for opioid dependence
In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a...
View ArticleClik here to view.
Relmada championing four pain drug candidates
Startup Relmada Therapeutics (OTCQB:RLMD) is in the enviable position of having multiple shots on goal in the world’s largest drug prescription market: the treatment of pain. Dr. Eliseo Salinas “It is...
View ArticleClik here to view.
Braeburn Pharma commends HHS plan on opioid addition
Closely-held Braeburn Pharmaceuticals has commended U.S. Department of Health and Human Services (HHS) Secretary Sylvia Burwell on her announcement that HHS will expand access to medication-assisted...
View ArticleClik here to view.
FDA accepts Probuphine NDA resubmission; Titan prepares for NASDAQ uplisting
The FDA has accepted for review an NDA for Titan Pharmaceuticals’ (OTCQB:TTNP) Probuphine, a six-month subdermal implant containing buprenorphine hydrochloride for the long-term maintenance treatment...
View ArticleClik here to view.
Knight to sublicense Titan Pharma’s Probuphine in Canada
Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive...
View ArticleClik here to view.
WB starts Collegium Pharma at outperform
William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday. Collegium’s lead...
View ArticleClik here to view.
Titan Pharma presents Phase 3 Probuphine data
Titan Pharmaceuticals (NASDAQ:TTNP) has presented data from the last Phase 3 study of Probuphine, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid...
View ArticleClik here to view.
Opioid addiction treatment continues to grab headlines
An article in the latest issue of Guernica, a magazine of art and politics, details the plight of doctors prescribing buprenorphine, a medication for the treatment of opiate addiction. Unlike...
View ArticleClik here to view.
Janney, Stifel start CARA Therapeutics at buy
Janney Capital Partners and Stifel Nicolas have initiated coverage CARA Therapeutics (NASDAQ:CARA) with “buy” ratings and a $25 fair value estimate and 12-month target price of $21, respectively. The...
View ArticleClik here to view.
FDA approves Titan’s Probuphine implant for opioid dependence
The FDA has approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or...
View ArticleClik here to view.
Roth ups Titan Pharma price target to $10
Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid...
View ArticleClik here to view.
Lipocine advancing pipeline, PDUFA for oral TRT
With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are...
View ArticleClik here to view.
Titan Pharma receives milestone on Probuphine approval
Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the...
View ArticleClik here to view.
Titan Pharma sensitivity analyses confirm efficacy of Probuphine
Titan Pharmaceuticals (NASDAQ: TTNP) is presenting data today from four post hoc sensitivity analyses of the final Phase 3 trial of Probuphine at a poster session during The College on Problems of Drug...
View Article
